204 related articles for article (PubMed ID: 28460619)
1. Targeting STEAP1 Protein in Human Cancer: Current Trends and Future Challenges.
Barroca-Ferreira J; Pais JP; Santos MM; Goncalves AM; Gomes IM; Sousa I; Rocha SM; Passarinha LA; Maia CJ
Curr Cancer Drug Targets; 2018; 18(3):222-230. PubMed ID: 28460619
[TBL] [Abstract][Full Text] [Related]
2. STEAP1 is overexpressed in cancers: a promising therapeutic target.
Moreaux J; Kassambara A; Hose D; Klein B
Biochem Biophys Res Commun; 2012 Dec; 429(3-4):148-55. PubMed ID: 23142226
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Intercellular Communication between Prostate Cancer Cells by A Specific Anti-STEAP-1 Single Chain Antibody.
Esmaeili SA; Nejatollahi F; Sahebkar A
Anticancer Agents Med Chem; 2018; 18(12):1674-1679. PubMed ID: 29219059
[TBL] [Abstract][Full Text] [Related]
4. Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.
Doran MG; Watson PA; Cheal SM; Spratt DE; Wongvipat J; Steckler JM; Carrasquillo JA; Evans MJ; Lewis JS
J Nucl Med; 2014 Dec; 55(12):2045-9. PubMed ID: 25453051
[TBL] [Abstract][Full Text] [Related]
5. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
[TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis of STEAP1 knockdown in human LNCaP prostate cancer cells.
Rocha SM; Santos FM; Socorro S; Passarinha LA; Maia CJ
Biochim Biophys Acta Mol Cell Res; 2023 Oct; 1870(7):119522. PubMed ID: 37315586
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens.
Gomes IM; Rocha SM; Gaspar C; Alvelos MI; Santos CR; Socorro S; Maia CJ
Med Oncol; 2018 Feb; 35(3):40. PubMed ID: 29464393
[TBL] [Abstract][Full Text] [Related]
8. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ
Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460
[TBL] [Abstract][Full Text] [Related]
9. Cryo-electron microscopy structure and potential enzymatic function of human six-transmembrane epithelial antigen of the prostate 1 (STEAP1).
Oosterheert W; Gros P
J Biol Chem; 2020 Jul; 295(28):9502-9512. PubMed ID: 32409586
[TBL] [Abstract][Full Text] [Related]
10. The Prognostic Role of STEAP1 Expression Determined via Immunohistochemistry Staining in Predicting Prognosis of Primary Colorectal Cancer: A Survival Analysis.
Lee CH; Chen SL; Sung WW; Lai HW; Hsieh MJ; Yen HH; Su TC; Chiou YH; Chen CY; Lin CY; Chen ML; Chen CJ
Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27104516
[TBL] [Abstract][Full Text] [Related]
11. STEAP1 is over-expressed in breast cancer and down-regulated by 17beta-estradiol in MCF-7 cells and in the rat mammary gland.
Maia CJ; Socorro S; Schmitt F; Santos CR
Endocrine; 2008; 34(1-3):108-16. PubMed ID: 18958632
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates in Prostate Cancer: Where Are we?
Mjaess G; Aoun F; Rassy E; Diamand R; Albisinni S; Roumeguère T
Clin Genitourin Cancer; 2023 Feb; 21(1):171-174. PubMed ID: 35999150
[TBL] [Abstract][Full Text] [Related]
13. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
Bhatia V; Kamat NV; Pariva TE; Wu LT; Tsao A; Sasaki K; Sun H; Javier G; Nutt S; Coleman I; Hitchcock L; Zhang A; Rudoy D; Gulati R; Patel RA; Roudier MP; True LD; Srivastava S; Morrissey CM; Haffner MC; Nelson PS; Priceman SJ; Ishihara J; Lee JK
Nat Commun; 2023 Apr; 14(1):2041. PubMed ID: 37041154
[TBL] [Abstract][Full Text] [Related]
14. Six transmembrane epithelial antigen of the prostate 1 is down-regulated by sex hormones in prostate cells.
Gomes IM; Santos CR; Socorro S; Maia CJ
Prostate; 2013 May; 73(6):605-13. PubMed ID: 23060075
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.
Cappuccini F; Stribbling S; Pollock E; Hill AV; Redchenko I
Cancer Immunol Immunother; 2016 Jun; 65(6):701-13. PubMed ID: 27052571
[TBL] [Abstract][Full Text] [Related]
16. STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma.
Ihlaseh-Catalano SM; Drigo SA; de Jesus CM; Domingues MA; Trindade Filho JC; de Camargo JL; Rogatto SR
Histopathology; 2013 Nov; 63(5):678-85. PubMed ID: 24025158
[TBL] [Abstract][Full Text] [Related]
17. STEAP proteins: from structure to applications in cancer therapy.
Gomes IM; Maia CJ; Santos CR
Mol Cancer Res; 2012 May; 10(5):573-87. PubMed ID: 22522456
[TBL] [Abstract][Full Text] [Related]
18. Targeting STEAP1 as an anticancer strategy.
Nakamura H; Arihara Y; Takada K
Front Oncol; 2023; 13():1285661. PubMed ID: 37909017
[TBL] [Abstract][Full Text] [Related]
19. STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors.
Grunewald TG; Diebold I; Esposito I; Plehm S; Hauer K; Thiel U; da Silva-Buttkus P; Neff F; Unland R; Müller-Tidow C; Zobywalski C; Lohrig K; Lewandrowski U; Sickmann A; Prazeres da Costa O; Görlach A; Cossarizza A; Butt E; Richter GH; Burdach S
Mol Cancer Res; 2012 Jan; 10(1):52-65. PubMed ID: 22080479
[TBL] [Abstract][Full Text] [Related]
20. The STEAP protein family: versatile oxidoreductases and targets for cancer immunotherapy with overlapping and distinct cellular functions.
Grunewald TG; Bach H; Cossarizza A; Matsumoto I
Biol Cell; 2012 Nov; 104(11):641-57. PubMed ID: 22804687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
